FDA Sends Warning Letters to 30 Telehealth Companies Over Misleading Compounded GLP-1 Ads

The FDA escalated its crackdown on compounded GLP-1 drugs today, issuing warning letters to 30 telehealth companies for making false or misleading claims about their compounded semaglutide and tirzepatide products.

This is the second wave of such letters. The first round, sent in September 2025, targeted companies including Eli Lilly, Novo Nordisk, and Hims & Hers. Today’s letters focus specifically on smaller telehealth firms that have continued marketing compounded GLP-1s aggressively — many of them after the official drug shortages ended.

What the Companies Did Wrong

The FDA cited two main violations:

1. False equivalence claims. Multiple companies claimed their compounded products were “the same as” FDA-approved GLP-1 drugs like Ozempic, Wegovy, Mounjaro, or Zepbound. They are not. Compounded drugs are not FDA-approved, have not been tested for safety or efficacy in clinical trials, and have no guarantee of consistent potency, sterility, or quality.

2. Hidden sourcing via rebrandng. Some companies put their own brand names on compounded products in ways designed to obscure that they were not the manufacturer. This practice — effectively passing off pharmacy-compounded drug as a proprietary product — violates FDA marketing rules and misleads patients about what they’re receiving.

“It’s a new era of enforcement,” FDA Commissioner Marty Makary said in a statement today. He warned that companies should not try to “circumvent FDA’s approval process by mass-marketing compounded drugs.”

Why This Matters for Patients

If you’re currently using a compounded GLP-1 product from a telehealth company, this enforcement wave is a signal — not necessarily about your immediate safety, but about the direction of the market.

The FDA has made a clear sequence of moves over the past 18 months:

• Declared the semaglutide shortage resolved (February 2025)
• Declared the tirzepatide shortage resolved (late 2024)
• Issued 90-day notice to stop compounded tirzepatide distribution
• Announced enforcement intent against mass-marketed compounded semaglutide
• Sent warning letters to 30+ companies today for false advertising

Each step narrows the window for compounded GLP-1 supply. Today’s letters don’t shut anyone down immediately — warning letters typically require a response within 15 business days and give companies time to correct violations. But companies that ignore them face injunctions, seizures, and potential criminal referrals.

What to Watch For

Patients who received compounded GLP-1 products from any of the 30 companies cited should watch their email and the company’s communications carefully. If a company receives an enforcement action beyond a warning letter, supply can be cut off with very short notice.

The FDA has not publicly named all 30 companies in today’s letters at the time of publication. Reuters and other outlets are reporting the overall number. We will update this article as the full list becomes available.

The Alternatives Right Now

For patients concerned about compounded supply stability, the FDA-approved path has become more accessible than it’s been in years:

• TrumpRx platform: Wegovy and Ozempic at approximately $350/month for uninsured patients at participating pharmacies
• GoodRx for Weight Loss: Oral semaglutide (Wegovy pill) starting at $149/month for lower doses
• Telehealth with FDA-approved prescriptions: Providers like Remedy Meds connect patients with licensed prescribers for brand-name GLP-1 medications
• Manufacturer assistance programs: Novo Nordisk and Eli Lilly both have patient assistance programs for eligible low-income patients

The era of compounded GLP-1s as a mainstream, readily available option is ending. The enforcement pressure is not random — it follows a clear regulatory logic. If you’re relying on a compounded source, the prudent move is to discuss a transition plan with your provider now, before the choice is made for you.

This article will be updated as more details from today’s FDA warning letters become available. Published March 3, 2026.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider about your GLP-1 treatment options.